Literature DB >> 12687643

Exploring the "two-hit hypothesis" in NF2: tests of two-hit and three-hit models of vestibular schwannoma development.

Ryan Woods1, J M Friedman, D Gareth R Evans, Michael E Baser, Harry Joe.   

Abstract

Neurofibromatosis 2 (NF2) is a genetic disease that occurs in approximately 1 in 40,000 live births. Almost all affected individuals develop bilateral tumors of Schwann cells that surround the vestibular nerves; these tumors are known as vestibular schwannomas (VS). Evidence from molecular genetic studies suggests that at least two mutations are involved in formation of VS in patients with NF2. Several authors proposed probabilistic models for this process in other tumors, and showed that such models are consistent with incidence data. We evaluated two different probabilistic models for a "2-hit" hypothesis for VS development in NF2 patients, and we present results from fitting these models to incidence data. Molecular evidence does not exclude the possibility that additional hits are necessary for the development of VS, and we also assessed a "3-hit" model for tumor formation. The "3-hit" model fits the data marginally better than one of the "2-hit" models and much better than the other "2-hit" model. Our findings suggest that more than two mutations may be necessary for VS development in NF2 patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12687643     DOI: 10.1002/gepi.10238

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  10 in total

Review 1.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

2.  A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.

Authors:  Chay Paterson; Ivana Bozic; Miriam J Smith; Xanthe Hoad; D Gareth R Evans
Journal:  Br J Cancer       Date:  2022-09-12       Impact factor: 9.075

3.  Epidemiology of vestibular schwannoma in the United States, 2004-2016.

Authors:  Gino Cioffi; Debra N Yeboa; Michael Kelly; Nirav Patil; Nauman Manzoor; Katie Greppin; Kailey Takaoka; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Adv       Date:  2020-10-10

4.  P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas.

Authors:  Ying Chen; Zhao-Yan Wang; Hao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

5.  Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.

Authors:  C Warren; L A James; R T Ramsden; A Wallace; M E Baser; J M Varley; D G Evans
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

6.  Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.

Authors:  Robin D S Doddrell; Xin-Peng Dun; Aditya Shivane; M Laura Feltri; Lawrence Wrabetz; Michael Wegner; Elisabeth Sock; C Oliver Hanemann; David B Parkinson
Journal:  Brain       Date:  2013-02       Impact factor: 13.501

Review 7.  The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.

Authors:  Hildegard Kehrer-Sawatzki; Said Farschtschi; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2016-12-05       Impact factor: 4.132

Review 8.  An update on the CNS manifestations of neurofibromatosis type 2.

Authors:  Shannon Coy; Rumana Rashid; Anat Stemmer-Rachamimov; Sandro Santagata
Journal:  Acta Neuropathol       Date:  2019-06-04       Impact factor: 17.088

Review 9.  Targeted Therapies for the Neurofibromatoses.

Authors:  Lauren D Sanchez; Ashley Bui; Laura J Klesse
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

10.  Intracranial meningioma in two coeval adult cats from the same litter.

Authors:  Ivona Orgonikova; Lorenzo Mari; Chiara Giannasi; Martí Pumarola I Batlle; Sebastien Behr; Josep Brocal
Journal:  JFMS Open Rep       Date:  2021-07-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.